Novartis Ag (NVS) EBITDA Margin (2009 - 2026)

Novartis Ag has disclosed EBITDA Margin across 18 years of filings, most recently posting 32.97% for Q2 2026.

• In Q2 2026, EBITDA Margin fell 164.0% year-over-year to 32.97%; the TTM figure through Jun 2026 stood at 33.49% (up 691.0% YoY), while the FY2025 annual figure was 32.36%, up 345.0% from the prior year.
• EBITDA Margin came in at 32.97% for Q2 2026 at Novartis Ag, up from 32.3% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 44.75% in Q1 2023 to a low of 14.96% in Q3 2023.
• Average EBITDA Margin over 5 years is 28.28%, with a median of 30.18% recorded in 2024.
• Year-over-year, EBITDA Margin slumped 942 bps in 2022 and soared 2199 bps in 2023.
• Over 5 years, EBITDA Margin stood at 19.57% in 2022, then grew by 8 bps to 21.13% in 2023, then decreased by 6 bps to 19.88% in 2024, then surged by 76 bps to 34.91% in 2025, then declined by 6 bps to 32.97% in 2026.
• Per Business Quant data, the three most recent EBITDA Margin figures were 32.97% in Q2 2026, 32.3% in Q1 2026, and 34.91% in Q4 2025.